Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of The Safety and Efficacy of CGT9486 in Subjects With Nonadvanced Systemic Mastocytosis

NCT05186753 is registered in ClinicalTrials.gov with Cogent Biosciences, Inc. as lead sponsor.

NCT NCT05186753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05186753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of The Safety and Efficacy of CGT9486 in Subjects With Nonadvanced Systemic Mastocytosis
Lead sponsor
Cogent Biosciences, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 27, 2022
Completion date
April 30, 2030
Enrollment
237 (estimated)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

bmm, bone marrow mastocytosis, ism, mastocytosis, mastocytosis, indolent, mastocytosis, systemic, smoldering systemic mastocytosis, ssm